- Home
- HLVX vs CBAT Comparison
HLVX vs CBAT Comparison
Compare HLVX & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- CBAT
- Stock Information
- Founded
- HLVX 2020
- CBAT 1999
- Country
- HLVX United States
- CBAT China
- Employees
- HLVX N/A
- CBAT N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- CBAT Industrial Machinery/Components
- Sector
- HLVX Health Care
- CBAT Miscellaneous
- Exchange
- HLVX Nasdaq
- CBAT Nasdaq
- Market Cap
- HLVX 87.6M
- CBAT 97.1M
- IPO Year
- HLVX 2022
- CBAT N/A
- Fundamental
- Price
- HLVX $1.89
- CBAT $0.95
- Analyst Decision
- HLVX Hold
- CBAT
- Analyst Count
- HLVX 5
- CBAT 0
- Target Price
- HLVX $2.33
- CBAT N/A
- AVG Volume (30 Days)
- HLVX 124.1K
- CBAT 320.9K
- Earning Date
- HLVX 11-07-2024
- CBAT 11-12-2024
- Dividend Yield
- HLVX N/A
- CBAT N/A
- EPS Growth
- HLVX N/A
- CBAT N/A
- EPS
- HLVX N/A
- CBAT 0.12
- Revenue
- HLVX N/A
- CBAT $207,423,403.00
- Revenue This Year
- HLVX N/A
- CBAT $10.76
- Revenue Next Year
- HLVX N/A
- CBAT $15.32
- P/E Ratio
- HLVX N/A
- CBAT $7.85
- Revenue Growth
- HLVX N/A
- CBAT 2.32
- 52 Week Low
- HLVX $1.55
- CBAT $0.79
- 52 Week High
- HLVX $20.22
- CBAT $2.08
- Technical
- Relative Strength Index (RSI)
- HLVX 50.42
- CBAT 35.79
- Support Level
- HLVX $1.80
- CBAT $0.92
- Resistance Level
- HLVX $2.02
- CBAT $1.15
- Average True Range (ATR)
- HLVX 0.08
- CBAT 0.06
- MACD
- HLVX 0.01
- CBAT -0.02
- Stochastic Oscillator
- HLVX 41.86
- CBAT 8.04
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization and distribution of a variety of standard and customized lithium-ion high-power rechargeable batteries. The company operates in two operating segments: CBAK's segment mainly includes the manufacture, commercialization and distribution of a wide variety of standard and customized lithium ion rechargeable batteries for use in a wide array of applications. Hitrans' segment mainly includes the development and manufacturing of NCM precursor and cathode materials. Geographically, it generates a majority of its revenue from Mainland China and also has an operation in Europe, the United States, Korea, and Other Countries.